Abbott Laboratories (NYSE:ABT) shares fell more than 2% in premarket trading on Wednesday after the healthcare and medical devices company reported third-quarter earnings that came in line with expectations, while sales narrowly missed consensus estimates.
Abbott posted earnings per share of $1.30, matching analyst forecasts. Revenue totaled $11.37 billion, slightly below the $11.4 billion expected. Overall sales increased 6.9% on a reported basis and 5.5% organically, rising to 7.5% when excluding contributions from COVID-19 testing.
“Our third-quarter results demonstrate our ability to deliver consistent, high-quality performance,” said Robert Ford, chairman and CEO of Abbott. “Our differentiated product pipeline continues to power our performance and positions Abbott to deliver durable long-term value to our shareholders.”
For the full year 2025, Abbott maintained its guidance, forecasting earnings between $5.12 and $5.18 per share, in line with the current consensus of $5.14.
The company also reaffirmed its outlook for organic sales growth of 7.5% to 8.0% excluding COVID testing impacts, and 6.0% to 7.0% including those revenues.
Abbott Laboratories stock price
This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.
Some portions of this content may have been generated or assisted by artificial intelligence (AI) tools and been reviewed for accuracy and quality by our editorial team.